“The first gains beyond today's study might be initial insight into the pathogenesis and neurobiology of brain development as influenced by these genetic variants,” he wrote, adding, “This knowledge will eventually enter the clinic and might affect the way people think about and treat neurodevelopmental disorders by accounting for the biological consequence of the specific patient's genotype.”
DR. BURBACH is with the department of neuroscience and pharmacology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands. He wrote a commentary accompanying the report (Lancet 2010 Sept. 30 [doi: 10.1016/S0140-6736(10)61192-0)]. He reported having no conflicts of interest.